Core Viewpoint - The launch of the "China 25" bone age evaluation system marks a significant advancement in the precise and standardized assessment of children's bone age in China, addressing the inadequacies of existing standards [1][3][6]. Group 1: Importance of Bone Age Evaluation - Bone age is a critical indicator for assessing children's growth and development, influencing height predictions and the diagnosis of endocrine diseases [3]. - Existing international standards like TW3 and G-P are not suitable for Chinese children due to ethnic and regional developmental differences [3]. Group 2: Development of "China 25" - The "China 25" system was developed over several years by a collaboration led by Beijing Jishuitan Hospital, involving multiple institutions, and is based on a large dataset of 20,166 X-ray images of normal children aged 3 to 18 from 28 locations across China [4][6]. - The new system incorporates a dual-blind annotation process and a data model tailored to contemporary Chinese children's developmental characteristics, highlighting the necessity for this new standard due to over a year of discrepancy with existing standards [4][6]. Group 3: Launch and Reception - The launch event featured prominent figures in the medical field, emphasizing the system's role in providing a "Chinese standard" for children's health management and supporting national health strategies [5][6]. - The large sample size of the data is considered a core advantage of the new standard, laying a solid foundation for future research in children's growth and development [5]. Group 4: Future Implications - The "China 25" has been published as a group standard and is set to play a crucial role in monitoring children's growth and diagnosing diseases, reflecting the country's commitment to children's health [6].